vimarsana.com
Home
Live Updates
PharmAbcine Announces First Patient Dosed in Phase 1a/b Clin
PharmAbcine Announces First Patient Dosed in Phase 1a/b Clin
PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors
/PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on next-generation antibody therapeutics, announced today the...
Related Keywords
South Korea ,
United States ,
Daejeon ,
Taejon Gwangyoksi ,
Australia ,
Jin San Yoo ,
Prnewswire Pharmabcine Inc ,
Youtube ,
Linkedin ,
Merck Co Inc ,
Merck Sharp Dohme ,
Pharmabcine Inc ,
Chief Executive Officer ,
Merck Sharp ,
Age Related Macular Degeneration ,
Tumor Microenvironment ,
Pharmabcine ,